Comparative Pharmacology
Head-to-head clinical analysis: CYCRIN versus ETHINYL ESTRADIOL ETONOGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCRIN versus ETHINYL ESTRADIOL ETONOGESTREL.
CYCRIN vs ETHINYL ESTRADIOL; ETONOGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
ETHINYL ESTRADIOL is an estrogen; ETONOGESTREL is a progestin. The combination suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial receptivity.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
One vaginal ring (0.120 mg etonogestrel/0.015 mg ethinyl estradiol per day) inserted vaginally and left in place for 3 weeks, followed by a 1-week ring-free period.
None Documented
None Documented
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Ethinyl estradiol: ~13 hours (range 7-20 h); etonogestrel: ~25 hours (range 15-36 h). At steady state, elimination half-life extends to 20-30 h for etonogestrel.
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Urine (60-70% as metabolites, <10% unchanged), feces (20-30% via biliary elimination).
Category C
Category D/X
Progestin
Progestin